The LC122M Non Coherent Light Sources… Making PDT Affordable: See us in Hall13 / Stand B62-5 in partnership with Lynton Lasers, LumaCare’s UK Distributor

LumaCare is a sponsor of the 24th Annual VCS Conference in Kansas City, MO November 4-6, 2004. Web site: http://www.vetcancersociety.org More information . . .      Model LC-122M Achieves Medical Device Directive      News and Events      See the LC122M at the ASP Meeting

See Us At: MEDICA Nov. 24-27, 2004!

LumaCare™ is a scientific company developing instrumentation products in the field of biotechnology. We have developed a specialized Non Coherent light source for the field of photodynamic therapy (PDT) and for universal use with new Biotech pharmaceuticals (such as Photofrin®, Visudyne® or 5-ALA). Photodynamic therapy is a safe, non-invasive treatment for numerous diseases, including psoriasis and other dermatological afflictions.

MBG Technologies, Inc. and our affiliate Ci-Tec U.K. have developed and own the intellectual property rights for a Non Coherent light source of flexible design: the LumaCare™ lamp. The LumaCare™ lamp is suitable for most photodynamic therapy applications and has the inherent clinical efficiency and cost/price structure to be suitable for a mass medical market distribution.

Photodynamic Therapy
Photodynamic therapy is one of the most promising new fields of medicine for the treatment of diseases and disorders of tissues. It involves the use of photoreactive drugs that are absorbed exclusively by diseased tissues while not affecting the surrounding healthy tissue.

The drugs are applied on the skin and penetrate through to the targeted diseased tissue, or they are injected into the blood stream, from which the affected area absorbs the drug.

Once the drugs are in place, the LumaCare™ lamp is used to irradiate the tissues with a fixed frequency light source unique to each drug and disease. The drug absorbs the light, which stimulates the drug to destroy only the diseased tissues in which the drug has been absorbed.

1. Light-activated drug is applied topically or injected intravenously.
2. Drug accumulates in the affected tissue.
3. Low power light is delivered through the LumaCare™ device and focused on the affected tissue.
4. Light activates photoreactive drug, releasing agents that destroy only affected cells.

The vast majority of photodynamic therapy applications utilize light waves in the 350-800 nanometer range--waves from the visible portion of the light spectrum. These wavelengths are preferred because they can penetrate up to 3 centimeters (over 1 1/8 inch) deep into human tissues. This means that targeted tissue beneath the skin's surface can be irradiated by light that is simply shined on the skin, avoiding any need for surgical procedures.